The application of tyrosine kinase inhibitors for the treatment of HER2‐positive patients causes obvious tumor cellular senescence, and notably, the cellular senescence caused by these inhibitors is not related to p16 or p21. The gene discussed is CDKN1A; the disease is neoplasm.